

Development of therapeutic candidate: Tie2 and Ang2 dual modulator for the next-generation treatment of wAMD and DR.



OPHTHALMOLOGY	Candidate
Product Type	Monoclonal antibody
Indication	<ul style="list-style-type: none"> • Wet age-related macular degeneration (AMD) • Diabetic retinopathy (DR)
Target	Angiopoietin-2 (Ang2) / Tie2
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Ang2 binding Tie2 activation agonist (ABTAA) • Sustained vessel remodeling and normalization • Strengthen endothelial cell-to-cell junction and prevent loss of pericyte • Suppress hypoxia in retinal tissue • Choriocapillaris regeneration
Competitiveness	<ul style="list-style-type: none"> • Provides therapy for anti-VEGF drug-refractory patients (approximately 30~50% of the patient population) • Offers systemic injection therapy to eliminate the burden of ocular injections.
Development Stage	Candidate
Route of Administration	<ul style="list-style-type: none"> • Intravitreal (IVT) • Subcutaneous (SC)